Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00637533 · ClinicalTrials.gov registry record · NA

A Pilot Clinical Trial of Sympathetic Blockade With Botulinum Toxin Type A to Treat Complex Regional Pain Syndrome (CRPS): a Randomized, Double-Blind, Controlled, Crossover Trial.

A NA study, sponsored by Stanford University.

Completed
Registry status
NA
Development phase
10
Enrollment target

NCT00637533: Completed NA study, sponsored by Stanford University.

NCT00637533 is a NA study that has completed, run by Stanford University. The registered enrollment target is 10 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00637533, a NA study, has completed, sponsored by Stanford University.

COMPLETED
Registry status
NA
Development phase
10 participants
Enrollment target

Study Summary

Lumbar sympathetic blocks are part of the standard of care for treating patients with sympathetically-maintained pain (e.g. in complex regional pain syndrome or reflex sympathetic dystrophy- RSD). In these patients lower extremity pain can be reduced or abolished temporarily by blocking sympathetic nerves by doing a lumbar sympathetic block. Patients who respond only transiently to sympathetic blocks often choose between potentially dangerous lumbar sympathetic block with neurolytic agents, surgical sympathectomy, continued severe refractory debilitating pain or other risky invasive surgical procedures such as spinal cord electrical stimulation.. It is hypothesized that Botulinum Toxin Type A (BTA) injected in a lumbar sympathetic block can provide extended sympathetic blockade and thus pain relief. This pilot study aims to see if BTA can be used safely in lower extremity sympathetic blocks, and might be useful in providing prolonged pain relief.

Interventions

  • PROCEDURE Lumbar sympathetic block with Botulinum Toxin type A

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2004-05
Est. Completion 2007-05
Phase NA
Stanford University

1,744 total trials

What the finished NCT00637533 record still lists

NCT00637533 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 1 intervention - of which Lumbar sympathetic block with Botulinum Toxin type A is the first listed.

NCT00637533 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00637533 about?

NCT00637533 is a clinical study titled "A Pilot Clinical Trial of Sympathetic Blockade With Botulinum Toxin Type A to Treat Complex Regional Pain Syndrome (CRPS): a Randomized, Double-Blind, Controlled, Crossover Trial.". Lumbar sympathetic blocks are part of the standard of care for treating patients with sympathetically-maintained pain (e.g. in complex regional pain syndrome or reflex sympathetic dystrophy- RSD). In these patients lower extremity pain can be reduced or abolished temporarily by blocking sympathetic ...

What is the current status of trial NCT00637533?

This trial is currently completed. It is a NA study. The enrollment target is 10 participants. The study started on 2004-05. Estimated completion is 2007-05.

What interventions are being tested in trial NCT00637533?

The interventions under investigation include: Lumbar sympathetic block with Botulinum Toxin type A (PROCEDURE).

Who is sponsoring clinical trial NCT00637533?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00637533's enrollment target sits among peer trials

10 1927th of 2000 higher than 26 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00637533, the US trial registry maintained by the National Library of Medicine. NCT00637533 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.